^
    Back
    Association details:
    Biomarker:CD31 expression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Front Oncol
    Title:

    Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

    Published date:
    07/10/2020
    Excerpt:
    ...Compared with that in the tumor masses treated with normal saline and other treatments, the decrease of CD31-immunolabeled cells in the tumor masses treated with anlotinib combined with chemoradiotherapy and anlotinib combined with radiotherapy was significant (P < 0.05)...
    DOI:
    10.3389/fonc.2020.00995